Video Experimental Relacionado
Updated: Feb 24, 2026
08:34
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
7.7K
Trisomía 13 como factor de riesgo de hipertensión pulmonar inducida por diazoxide
Kazu Ishikawa1,2, Hiro Nakao1,2, Daisuke Shinjo3
1Center for Postgraduate Education and Training, National Center for Child Health and Development, Tokyo, Japan.
Annals of pediatric cardiology
|February 23, 2026
Resumen
El diazoxide puede causar hipertensión pulmonar (HP) en lactantes. La Trisomía 13 aumenta significativamente este riesgo, incluso con dosis bajas y diuréticos, lo que subraya la necesidad de precaución en los recién nacidos afectados.
Área de la Ciencia:
- Farmacología pediátrica
- Cardiología
- Genética
Sus antecedentes:
- El diazoxide es un tratamiento clave para la hipoglucemia hiperinsulinémica.
- La hipertensión pulmonar (HP) es una reacción adversa grave a los medicamentos asociada con el diazoxide.
- Es crucial comprender el riesgo basal de HP inducida por diazoxide.
Objetivo del estudio:
- Determinar el riesgo basal de desarrollar hipertensión pulmonar (HP) tras la administración de diazoxide.
- Identificar los factores de riesgo de HP en niños tratados con diazoxide.
Principales métodos:
- Estudio de cohortes retrospectivo de 65 niños menores de 15 años tratados con diazoxide para hiperinsulinemia congénita.
- Se extrajeron datos de historias clínicas electrónicas, centrándose en el desarrollo de HP y los antecedentes del paciente.
- Se aplicó estimación bayesiana para evaluar el riesgo de HP.
Principales resultados:
- 5% de los niños (3 de 65) desarrollaron HP.
- La Trisomía 13 fue un factor de riesgo significativo de HP (100% frente a 0%, P < 0,001).
- Un menor peso al nacer también se asoció con el desarrollo de HP (P = 0,049).
Conclusiones:
- La Trisomía 13 eleva sustancialmente el riesgo de HP con el uso de diazoxide.
- Los diuréticos profilácticos y el diazoxide a dosis bajas pueden no prevenir la HP en pacientes con Trisomía 13.
- Se recomienda precaución al prescribir diazoxide a lactantes con Trisomía 13 y bajo peso al nacer.
Videos de Conceptos Relacionados
01:30Pulmonary Hypertension: Classification and Pathogenesis
703
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
703
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
671
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
671
01:26Pneumothorax-I
1.7K
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
1.7K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
506
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
506
01:29Pulmonary Embolism I: Introduction
942
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
942
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
3.9K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.9K